ArticleCell death discovery2022

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft.

Mengqi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.